The placebo effect in oncology trials and the criteria for approving drugs

Breast-conserving therapy may be option for multiple breast lesions

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1

ASH 2022: Multiple myeloma roundup

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery

Updates from TAILORx and RxPONDER: Implications for practice

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse